Zosano Pharma (ZSAN) Peer Comparison
$0.30
$-0.03
(-9.23%)
As on 08-Jul-2022 09:30EDT
Market cap
$3 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
0.2
Div. Yield
0 %
Edit
| Zosano Pharma (ZSAN) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
3 | 2,945 | 2,249 | 2,449 | 1,129 |
Revenue ($ Mln) |
1 | 450 | 121 | 549 | 4 |
Net Profit ($ Mln) |
-55.19 | -188.21 | -57.76 | 17.88 | -340.16 |
Net Margin (%) |
-2,199.76 | -41.86 | -47.82 | 3.26 | -540.52 |
RoE (%) |
-211.23 | -28.46 | -9.91 | 1.43 | 501.41 |
Price to Earnings |
-- | -- | -- | 140.90 | -- |
Price-To-Book |
0.16 | 4.90 | 3.92 | 1.66 | 2.10 |
Income Statement ($ Mln)
| Zosano Pharma (ZSAN) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.66 | 144.31 | 7.46 | 356.13 | 4.19 |
|
Cost of Revenue
|
0.72 | 52.24 | 85.73 | 28.79 | 1.02 |
|
Gross Profit
|
-0.01 | 92.07 | -78.28 | 327.34 | 4.19 |
|
Operating Expenses
|
30.80 | 792.14 | 115.06 | 684.45 | 56.31 |
|
Operating Profit (EBIT)
|
-56.80 | -700.06 | -109.10 | -357.10 | -52.11 |
|
Other Income
|
1.85 | -- | -- | -- | -- |
|
Profit before Tax
|
-55.19 | -703.41 | -99.63 | -155.12 | -49.27 |
|
Provision for Tax
|
0.00 | 1.06 | -0.82 | 11.92 | 0.36 |
|
Profit after Tax (Net Income)
|
-55.19 | -704.47 | -98.81 | -194.65 | -49.64 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Consolidated Profit
|
-55.19 | -704.47 | -98.81 | -194.65 | -49.64 |
Liabilities ($ Mln)
| Zosano Pharma (ZSAN) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
14.05 | 1,379.96 | 581.40 | 986.89 | 88.87 |
|
Minority Interest
|
0.00 | -- | -- | -- | -- |
|
Non-Current Liabilities
|
2.66 | 37.10 | 69.05 | 21.49 | 10.27 |
|
Current Liabilities
|
9.73 | 192.90 | 94.27 | 311.66 | 22.85 |
|
Total Liabilities
|
48.39 | 1,609.96 | 744.72 | 1,372.66 | 121.99 |
Assets ($ Mln)
| Zosano Pharma (ZSAN) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
10.81 | 109.08 | 596.49 | 160.59 | 6.41 |
|
Current Assets
|
15.63 | 1,500.88 | 148.23 | 1,212.08 | 115.58 |
|
Total Assets
|
48.39 | 1,609.96 | 744.72 | 1,372.66 | 121.99 |
|
Total Debt*
|
6.04 | 15.54 | 105.50 | 38.98 | 10.12 |
|
Net Current Assets
|
5.90 | 1,307.98 | 53.95 | 900.42 | 92.73 |
Cashflow ($ Mln)
| Zosano Pharma (ZSAN) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-27.59 | -549.23 | -106.68 | -204.22 | -47.63 |
|
Cash Flow from Investing Activities
|
-5.42 | 249.96 | -1.65 | -306.32 | -1.79 |
|
Cash from Financing Activities
|
8.79 | 820.20 | 114.47 | 650.03 | 25.45 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Zosano Pharma (ZSAN) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-56.04 | -54.54 | -14.80 | -25.13 | -45.07 |
|
ROE (%)
|
-211.23 | -55.27 | -17.48 | -26.46 | -49.62 |
|
ROA (%)
|
-94.92 | -48.46 | -13.37 | -18.57 | -38.05 |
|
EBIT Margin (%)
|
-8,350.08 | -- | -- | -- | -- |
|
Net Margin (%)
|
-2,199.76 | -488.16 | -1,325.25 | -54.66 | -1,183.50 |
|
Cash Profit Margin (%)
|
-0.01 | -- | -- | -- | -- |
Growth Ratios
| Zosano Pharma (ZSAN) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
36.72 | 1.95 | -0.77 | 0.56 | 10.27 |
|
EBIT Growth (%)
|
-128.26 | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-123.23 | -161.98 | -26.78 | -54.55 | -56.96 |
|
EPS Growth (%)
|
-- | -1.40 | -0.07 | -0.31 | -0.52 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Zosano Pharma (ZSAN) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -85.15 | -4.90 | -30.86 | -10.90 |
|
Price / Book Value
|
-- | 43.47 | 0.83 | 6.09 | 6.09 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
0.06 | -84.98 | -5.35 | -32.58 | -8.64 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Zosano Pharma (ZSAN) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.01 | 0.18 | 0.04 | 0.11 |
|
Short term debt to equity ratio
|
0.24 | 0.00 | 0.10 | 0.03 | 0.01 |
|
Current Ratio
|
1.61 | 7.78 | 1.57 | 3.89 | 5.06 |
|
Quick Ratio
|
1.61 | 7.68 | 1.57 | 3.77 | 5.04 |
|
Interest Coverage
|
-333.50 | -207.75 | -8.30 | -363.43 | -388.55 |
Operating Efficiency Ratios
| Zosano Pharma (ZSAN) | Zai Lab - ADR | Mesoblast - ADR | HUTCHMED (China) - ADR | Inventiva Sa (IVA) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
16.24 | 37.98 | 61.56 | 41.48 | 276.28 |
|
Asset Turnover
|
0.01 | 0.10 | 0.01 | 0.34 | 0.03 |
|
Receivable days
|
62.81 | 75.90 | 144.81 | 100.31 | 506.64 |
|
Inventory Days
|
-- | 112.20 | -1.07 | 352.24 | 127.86 |
|
Payable days
|
918.63 | 660.05 | 94.94 | 461.79 | 3,865.30 |
|
Cash Conversion Cycle
|
-- | -471.95 | 48.79 | -9.25 | -3,230.80 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
